Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy.
advanced intrahepatic cholangiocarcinoma
conversion therapy
next-generation sequencing
surgery
systemic sequential therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
04
2021
accepted:
06
08
2021
entrez:
16
9
2021
pubmed:
17
9
2021
medline:
17
9
2021
Statut:
epublish
Résumé
Intrahepatic cholangiocarcinoma (CCA), always diagnosed at an advanced stage in recent years, is of high aggression and poor prognosis. There is no standard treatment beyond first-line chemotherapy and no molecular-targeted agents or immune checkpoint inhibitors approved for advanced intrahepatic CCA. Hence, we firstly report an original therapeutic strategy for a 60-year-old patient diagnosed with intrahepatic CCA categorized as Stage IIIB (T3N1M0) by the American Joint Committee on Cancer staging system. After histopathological examination and next-generation sequencing, the patient was treated with four courses of novel systemic sequential therapy (intravenous gemcitabine 1,000 mg/m
Identifiants
pubmed: 34527576
doi: 10.3389/fonc.2021.691380
pmc: PMC8435785
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
691380Informations de copyright
Copyright © 2021 Ding, Han, Sun, Tang, Wu and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer QX and the handling editor JC declared a shared affiliation, with no collaboration, with the authors, at the time of the review.
Références
Int J Cancer. 2020 Oct 15;147(8):2190-2198
pubmed: 32359091
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Semin Cancer Biol. 2020 Nov 26;:
pubmed: 33249201
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Ann Oncol. 2016 Sep;27(suppl 5):v28-v37
pubmed: 27664259
Cancer Discov. 2017 Sep;7(9):943-962
pubmed: 28818953
Cancer Control. 2017 Jul-Sep;24(3):1073274817729245
pubmed: 28975830
BMC Cancer. 2020 Nov 16;20(1):1105
pubmed: 33198671
Hepatobiliary Surg Nutr. 2020 Dec;9(6):777-779
pubmed: 33299833
Lancet Gastroenterol Hepatol. 2019 Sep;4(9):711-720
pubmed: 31300360
Oncologist. 2020 Jan;25(1):e147-e159
pubmed: 31578273
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
Cell Immunol. 2014 Jul;290(1):72-9
pubmed: 24908630
Hepatology. 2019 Apr;69(4):1803-1815
pubmed: 30251463
Immunity. 2013 Jul 25;39(1):74-88
pubmed: 23890065
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111
pubmed: 28994423
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
Pharmacol Ther. 2018 Sep;189:45-62
pubmed: 29669262
Stem Cells Int. 2019 Feb 19;2019:3831213
pubmed: 30915124
HPB (Oxford). 2015 Apr;17(4):344-51
pubmed: 25395176
Drugs. 2020 Apr;80(6):617-624
pubmed: 32185681
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Drugs. 2015 Apr;75(5):553-60
pubmed: 25795101
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
Ann Surg Oncol. 2016 Aug;23(8):2610-7
pubmed: 27012989
Surg Oncol Clin N Am. 2019 Oct;28(4):587-599
pubmed: 31472907
J Hepatol. 2018 May;68(5):959-969
pubmed: 29360550
J Gastroenterol. 2020 Oct;55(10):944-957
pubmed: 32748173
J Clin Oncol. 2020 Sep 10;38(26):2960-2970
pubmed: 32716739
J Am Coll Surg. 2009 Feb;208(2):218-28
pubmed: 19228533
Gastroenterology. 2013 Dec;145(6):1215-29
pubmed: 24140396
Gut Liver. 2009 Dec;3(4):298-305
pubmed: 20431764
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Lancet Oncol. 2019 Sep;20(9):1306-1315
pubmed: 31378459